BIOASIS TECHNOLOGIES INC - BIOAF STOCK NEWS

Bioasis Technologies has announced the closure of initial funding amounting to C$3 million under a convertible security agreement with Lind Global Macro Fund. After a closing fee of C$90,000, the net funding stands at C$2.91 million. The company also issued 4,839,048 warrants, exercisable at $0.41 per share over the next 30 months. The funds will be allocated for general working capital. This financing was conditionally approved by the TSX Venture Exchange on June 23, 2021, and is subject to a four-month hold period.

Bioasis Technologies Inc. (BIOAF) has filed its audited annual financial statements for the period ending February 28, 2021. The company is in the pre-clinical stage, focusing on developing its proprietary xB³™ platform technology aimed at delivering therapeutics across the blood-brain barrier for CNS disorders such as brain cancers and neurodegenerative diseases. The documents are available on SEDAR and the company's website, highlighting its commitment to address significant unmet medical needs in these areas.

Bioasis Technologies has announced a convertible security funding agreement with Lind Global Macro Fund for up to C$10 million, with an initial investment of C$3 million. The funds will support Bioasis’ xB^3TM platform, aimed at delivering therapeutics across the blood-brain barrier. The agreement includes terms for repayment and conversion of securities into common shares at C$0.31. Bioasis is positioned to leverage its research in CNS disorders despite previous challenges in study completion due to external constraints.

BIOASIS TECHNOLOGIES INC (TSXV:BTI; OTCQB:BIOAF) announced research validating its xB³™ platform's ability to cross the blood-brain barrier (BBB) and localize in various brain cell types. Conducted by Professor Wilfred Jefferies and Bioasis scientists, the study shows the platform's potential in treating CNS disorders such as brain cancers and neurodegenerative diseases. Published in Frontiers in Neuroscience, the data highlight the ability of peptides from melanotransferrin to deliver therapeutics effectively across the BBB.

Bioasis Technologies Inc. (OTCQB:BIOAF) has announced a research collaboration with Aposense Limited to enhance the delivery of siRNA therapies for neurological disorders. The partnership aims to leverage Bioasis’ xB³ platform, which enables the non-invasive delivery of genetic therapies across the blood-brain barrier. Recent data indicates that xB³ can effectively knock down the NOX4 gene in stroke models, signaling potential for treating severe conditions.

Bioasis Technologies Inc. (TSXV:BTI; OTCQB:BIOAF) announced a significant milestone on March 29, 2021, with the publication of research validating its xB³™ platform for delivering siRNA across the blood-brain barrier (BBB). Conducted by Bioasis scientists and Dr. Wilfred A. Jefferies, the study demonstrated that the xB³™ platform can effectively deliver therapeutic doses, reducing stroke damage and enhancing neurological function in an ischemic stroke model. This research supports Bioasis’s ongoing mission to develop treatments for CNS disorders, particularly in areas with high unmet medical needs.

Bioasis Technologies Inc. (TSXV:BTI; OTCQB:BIOAF) announced plans to extend the expiry date of 5,797,795 common share purchase warrants from April 11, 2021, to April 11, 2022. The exercise price will also be reduced from $1.00 to $0.85. This adjustment is part of a private placement from April 2017 and is subject to TSX Venture Exchange approval. Bioasis focuses on developing its xB³™ platform to deliver therapeutics for CNS disorders, including brain cancers and neurodegenerative diseases.

Bioasis Technologies (OTCQB:BIOAF) announced Dr. Deborah Rathjen, CEO, will present at the M-Vest LLC and Maxim Group's Emerging Growth Virtual Conference from March 17-19, 2021. The conference will feature discussions with executives and company presentations. Additionally, Dr. Rathjen will participate in the 4th Annual Neuroscience Innovation Forum from April 28-30, 2021, where she'll engage in panel discussions and corporate presentations regarding advancements in Alzheimer's and dementia treatment. Bioasis focuses on its xB³™ platform for delivering therapeutics across the blood-brain barrier.

Bioasis Technologies (OTCQB:BIOAF) announced on February 10, 2021, that it will issue 300,000 common shares at a price of $0.3975 per share to a third party to settle a contractual dispute. This shares-for-debt agreement is pending approval from the TSX Venture Exchange and will be subject to a four-month hold period post-issuance. The company focuses on delivering therapeutics across the blood-brain barrier, addressing significant medical needs in CNS disorders like brain cancers and neurodegenerative diseases.